Delcath(US:DCTH)2026-02-26 14:30Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $85.2 million, representing over 40% volume growth compared to the previous year [6][19] - The fourth quarter revenue was $20.7 million, with HEPZATO sales at $19 million and CHEMOSAT at $1.7 million, compared to $13.7 million and $1.4 million respectively in Q4 2025 [19] - Gross margins were 85% in Q4 and 86% for the full year, compared to 86% and 83% in the prior year [19] - The net loss for Q4 2025 was $1.9 million, an improvement from a $3.4 million loss in Q4 2024, while the full year net income was $2.7 million compared to a loss of $26.4 million in 2024 [21] Business Line Data and Key Metrics Changes - Revenue from HEPZATO increased significantly from $32.3 million in 2024 to $78.8 million in 2025, while CHEMOSAT revenue rose from $4.9 million to $6.4 million [19] - The average number of treatments per patient has remained consistent at approximately four cycles since launch [7] Market Data and Key Metrics Changes - The company operates 28 active treatment centers and aims to expand to 40 by the end of 2026 [9] - The average rate of new patient starts per site per month was approximately 0.75 for the first two months of 2026, compared to an average of 0.5 for the full year of 2025 [11] Company Strategy and Development Direction - The company’s commercial strategy focuses on three priorities: expanding site capacity, changing prescribing patterns, and building referral networks [7][15] - The CHOPIN data publication is anticipated to drive revenue acceleration and enhance the company’s market position [6][12] - The company is actively engaging key opinion leaders to support updates to the NCCN guidelines for metastatic uveal melanoma [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth driven by site activations and the anticipated impact of the CHOPIN results [6][15] - The company expects to guide total revenue of at least $100 million for 2026, reflecting a greater than 20% increase in HEPZATO procedure volume [22][23] Other Important Information - Research and development expenses for 2025 were $29.2 million, up from $13.9 million in 2024, with expectations for a nearly 90% increase in 2026 [20] - The company ended 2025 with approximately $91 million in cash and investments, and no outstanding debt obligations [22] Q&A Session Summary Question: Clarification on guidance assumptions and seasonality - Management confirmed that seasonality is expected in the third quarter, with modest growth anticipated from Q2 to Q3 [26][28] Question: Difference between HEPZATO KIT REMS sites and clinical trial sites - Management clarified that HEPZATO KIT REMS sites must be compliant and cannot accept referrals until they have treated their first patient [31][33] Question: Timing of CHOPIN study publication and its impact - Management indicated that the CHOPIN study publication is imminent, expected within a month, and will be used to educate treating physicians [39] Question: Average treatments per patient and new patient starts - The average treatments per patient remain around 4.1, with intervals stretching closer to 8 weeks [45][48] Question: Potential for NCCN guideline updates - Management noted that updates to the NCCN guidelines are driven by key opinion leaders and are hopeful for changes based on new data [82]